Trodelvy Shows Promise in Triple-Negative Breast Cancer Trial
Gilead Sciences’ Trodelvy has secured a significant win with its phase 3 trial results, demonstrating improved progression-free survival when combined with Keytruda for first-line triple-negative breast cancer (TNBC). The Ascent-04 trial, which targeted patients whose tumors express PD-L1, found that the combination of Trodelvy and Keytruda outperformed chemotherapy in prolonging time before cancer recurrence or … Read more